ArticleJournal of the National Cancer Center2026
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses.
Zhicheng Lai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.